Astrazeneca Pharma India is currently trading at Rs. 7050.00, up by 210.35 points or 3.08% from its previous closing of Rs. 6839.65 on the BSE.
The scrip opened at Rs. 6900.00 and has touched a high and low of Rs. 7099.60 and Rs. 6762.90 respectively. So far 390 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 8139.85 on 30-Sep-2024 and a 52 week low of Rs. 4050.15 on 21-Mar-2024.
Last one week high and low of the scrip stood at Rs. 7154.50 and Rs. 6609.60 respectively. The current market cap of the company is Rs. 17625.13 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 8.14% and 16.87% respectively.
AstraZeneca Pharma India has received approval from drug regulator - Central Drugs Standard Control Organisation (CDSCO) to import and distribute cancer treatment medicine Durvalumab solutions in the country. The approval by CDSCO, Directorate General of Health Services, Government of India is for import, for sale and distribution of Durvalumab solution for infusion 120 mg/2.4 ml and 500 mg/10 ml (Imfinzi) for an additional indication.
Durvalumab in combination with Tremelimumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC). The receipt of this permission paves way for the marketing of Durvalumab solution for infusion 120 mg/2.4 ml and 500 mg/10 ml (Imfinzi) in India for the specified additional indication, subject to the receipt of related statutory approvals.
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1785.30 |
| Dr. Reddys Lab | 1210.00 |
| Cipla | 1524.35 |
| Lupin | 2121.30 |
| Zydus Lifesciences | 926.60 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
100% Secure Process
Account Discovery
- OTP from CAMS
Account Linking for Stocks & MF
- One OTP per link Eg. NSDL, CDSL, CAMS, KFin etc.
One Click Upload for your Current Portfolio and Future Transactions!
Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
